KPIs & Operating Metrics(New)
Growth Metrics

Xylem (XYL) EBIT (2016 - 2026)

Xylem has reported EBIT over the past 17 years, most recently at $244.0 million for Q1 2026.

  • For Q1 2026, EBIT rose 5.63% year-over-year to $244.0 million; the TTM value through Mar 2026 reached $1.2 billion, up 19.88%, while the annual FY2025 figure was $1.2 billion, 21.21% up from the prior year.
  • EBIT for Q1 2026 was $244.0 million at Xylem, down from $353.0 million in the prior quarter.
  • Over five years, EBIT peaked at $353.0 million in Q4 2025 and troughed at $111.0 million in Q1 2022.
  • A 5-year average of $220.6 million and a median of $211.0 million in 2023 define the central range for EBIT.
  • Biggest five-year swings in EBIT: fell 18.49% in 2023 and later skyrocketed 112.61% in 2024.
  • Year by year, EBIT stood at $197.0 million in 2022, then grew by 7.11% to $211.0 million in 2023, then increased by 26.54% to $267.0 million in 2024, then surged by 32.21% to $353.0 million in 2025, then plummeted by 30.88% to $244.0 million in 2026.
  • Business Quant data shows EBIT for XYL at $244.0 million in Q1 2026, $353.0 million in Q4 2025, and $334.0 million in Q3 2025.